TP53 and Burkitt lymphoma: SNV/indels of TP53 were significantly associated with a cumulative incidence of progression or relapse of 25 ± 4%, compared to 6 ± 2% for BL with TP53 wild-type status (Fig. 5B, P = 0.0002).